United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,416	11/10/2003	Kathryn E. Uhrich	1435.010US3	7606
	7590 06/27/2007 RRIS & PADYS PLLP		EXAMINER	
P.O. BOX 111098		4.	FUBARA, BLESSING M	
SI. FAUL, MIN	ST. PAUL, MN 55111-1098		ART UNIT	PAPER NUMBER
			1618	
	•			
			MAIL DATE	DELIVERY MODE
			06/27/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/712,416	UHRICH, KATHRYN E.
Office Action Summary	Examiner	Art Unit
	Blessing M. Fubara	1618
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wit	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory perion - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC 1.136(a). In no event, however, may a re od will apply and will expire SIX (6) MON tute, cause the application to become AB.	CATION. Poply be timely filed ITHS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 10 2a) This action is FINAL. 2b) The 3) Since this application is in condition for allow closed in accordance with the practice under the second se	his action is non-final. wance except for formal matte	• •
Disposition of Claims		
4) ⊠ Claim(s) <u>1-35</u> is/are pending in the application 4a) Of the above claim(s) is/are withdrest is/are allowed. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-35</u> are subject to restriction and/or	rawn from consideration.	
Application Papers		
9) The specification is objected to by the Exami 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ccepted or b) objected to be drawing(s) be held in abeyand ection is required if the drawing(ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a li	ents have been received. ents have been received in Apriority documents have been eau (PCT Rule 17.2(a)).	oplication No received in this National Stage
Attachment(s)	"□··· -	(DTO 440)
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 3/13/06. 	Paper No(s	ummary (PTO-413))/Mail Date formal Patent Application

DETAILED ACTION

Election Requirements

1. Claim 1 generic to the following disclosed patentably distinct species: The polymer in claim 1 encompasses different polymers, the varied polymers are ones where the degradable bond is a) anhydride, b) amide, c) thioester and d) ester, so that the degradation of each type of bond releases different drug. The species are independent or distinct because each bond is different giving rise to polymers that are capable of supporting different patents within the art. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Therefore, applicant is requested to elect a specific polymer that upon degradation releases a specific disclosed bioactive agent by electing:

- i) anhydride, amide, thioester or ester linkage
- ii) non-steroidal anti-inflammatory drug, anti-bacterial drug, anti-fungal drug, anti-cancer drug, antithrombotic drug, immunosuppressive drug, analgesic drug or anesthetic drug
- iii) and with the election of the specific linkage, and thus, specific polymer degrading to generate specific class of active agent according to the election in item ii), elect the drug that is specific to the class/group of drug generated from that linkage group.
- 2. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/712,416

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 4

Blessing Fubara

Patent Examiner

Tech. Center 1600